Puma Biotechnology Inc (NASDAQ:PBYI) is expected to report third quarter earnings results, after market close, on Thursday 5th November 2020.
Analysts polled by Thomson Reuters anticipate third quarter loss of $ 0.39 per share.
Looking ahead, the full year loss are expected at $ 1.04 per share on the revenues of $ 232.99 million.
Previous Quarter Performance
Puma Biotechnology Inc communicated income for the second quarter of $ 0.35 per share, from the revenue of $ 70.60 million. The quarterly revenues improved 30.98 percent compared with the same quarter last year. According to street consensus, PBYI was expected to report 2Q20 loss of $ 0.30 per share from revenue of $ 58.21 million. The bottom line results beat street analysts by $ 0.65 or 216.67 percent, at the same time, top line results outshined analysts by $ 12.39 million or 21.29 percent.
Stock Performance
Shares of Puma Biotechnology Inc traded up $ 0.81 or 10.21 percent on Wednesday, reaching $ 8.74 with volume of 620.70 thousand shares. Puma Biotechnology Inc has traded high as $ 8.91 and has cracked $ 7.90 on the downward trend
The closing price of $ 8.74, representing a 44.18 % increase from the 52 week low of $ 5.50 and a 47.13 % decrease over the 52 week high of $ 15.00.
The company has a market capital of $ 346.78 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Puma Biotechnology Inc will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.pumabiotechnology.com
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care. Its drug candidates include PB272 neratinib (oral) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 neratinib (intravenous). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4.
